O-RADS US风险分层与管理系统的外部验证
本研究回顾性纳入2015年8月至2017年4月在一家三级肿瘤转诊中心接受盆腔超声的连续女性,评估O-RADS US对卵巢及附件病变良恶性鉴别效能,并与IOTA ADNEX模型比较;O-RADS US的AUC为0.91,ADNEX为0.95,将声影作为良性征象纳入后O-RADS的AUC提高至0.94。
要点
- O-RADS 2至5类的恶性比例分别为0%(0/100)、3%(1/32)、35%(22/63)和78%(52/67)。
- O-RADS US与ADNEX模型的AUC分别为0.91和0.95,ADNEX略优。
- 以O-RADS 4类为阈值,敏感度为99%(74/75),特异度为70%(131/187)。
核心结论
- 在一家三级肿瘤转诊中心,O-RADS US能准确区分卵巢及附件病变的良恶性,将声影作为良性征象可提高其诊断效能。
研究设计与样本
- 回顾性研究,纳入2015年8月至2017年4月在一家三级肿瘤转诊中心接受盆腔超声的连续女性227例(平均年龄52岁±16),共262个卵巢或附件病变;两名独立阅片者对临床及组织学结果盲法,分别赋予O-RADS风险类别和IOTA ADNEX恶性风险评分;参考标准为手术组织病理学或2年影像随访。
关键影像表现/征象
- 262个病变中良性187个(71%)、恶性75个(29%)。
- O-RADS 2类恶性比例为0%(0/100),3类为3%(1/32),4类为35%(22/63),5类为78%(52/67)。
诊断标准与关键数值
- O-RADS US的AUC为0.91(95%CI:0.88,0.94),ADNEX模型的AUC为0.95(95%CI:0.92,0.97),两者差异P=.01。
- 将声影作为良性征象纳入后,O-RADS的AUC提高至0.94(95%CI:0.91,0.96),与未纳入声影的O-RADS相比P=.01。
- 以O-RADS 4类为阈值,敏感度为99%(74/75;95%CI:96,100),特异度为70%(131/187;95%CI:64,77)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The Ovarian-Adnexal Reporting and Data System (O-RADS) US risk stratification and management system (O-RADS US) was designed to improve risk assessment and management of ovarian and adnexal lesions. Validation studies including both surgical and nonsurgical treatment as the reference standard remain lacking. Purpose To externally validate O-RADS US in women who underwent either surgical or nonsurgical treatment and to determine if incorporating acoustic shadowing as a benign finding improves diagnostic performance. Materials and Methods This retrospective study included consecutive women who underwent pelvic US between August 2015 and April 2017 at a tertiary referral oncology center. Two independent readers blinded to clinical and histologic outcome assigned an O-RADS risk category and an International Ovarian Tumor Analysis (IOTA) Assessment of Different NEoplasias in the adneXa (ADNEX) model risk of malignancy score to assessable lesions. Reference standards were surgical histopathology or 2-year imaging follow-up. Receiver operating characteristic (ROC) curve analysis was used to evaluate performance of the O-RADS US, ADNEX, and modified O-RADS models incorporating acoustic shadowing. Results In total, 227 women (mean age, 52 years ± 16 [SD]) with 262 ovarian or adnexal lesions were evaluated. Of these lesions, 187 (71%) were benign and 75 (29%) were malignant. The proportion of malignancy was 0% (0 of 100) for O-RADS 2, 3% (one of 32) for O-RADS 3, 35% (22 of 63) for O-RADS 4, and 78% (52 of 67) for O-RADS 5. The area under the ROC curve (AUC) for O-RADS and ADNEX was 0.91 (95% CI: 0.88, 0.94) and 0.95 (95% CI: 0.92, 0.97; P = .01), respectively. The addition of acoustic shadowing as a benign finding improved O-RADS AUC to 0.94 (95% CI: 0.91, 0.96; P = .01). Use of O-RADS 4 as a threshold yielded a sensitivity of 99% (74 of 75; 95% CI: 96, 100) and a specificity of 70% (131 of 187; 95% CI: 64, 77). Conclusion In a tertiary referral oncology center, the Ovarian-Adnexal Reporting and Data System US risk stratification and management system enabled accurate distinction of benign from malignant ovarian and adnexal lesions. Adding acoustic shadowing as a benign finding improved its diagnostic performance. © RSNA, 2022 See also the editorial by Levine in this issue.
引用
- Hack, Gandhi, Bouchard-Fortier, et al. External Validation of O-RADS US Risk Stratification and Management System. Radiology. 2022. PMID: 35438559. doi:10.1148/radiol.211868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。